Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells 64,533 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 64,533 shares of the stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $25.69, for a total transaction of $1,657,852.77. Following the completion of the transaction, the insider directly owned 78,518 shares in the company, valued at $2,017,127.42. This trade represents a 45.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Campbell Rogers also recently made the following trade(s):

• On Thursday, February 12th, Campbell Rogers sold 65,153 shares of Heartflow stock. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97.

Heartflow Stock Performance

NASDAQ HTFL traded up $0.80 during trading hours on Monday, hitting $26.82. The company had a trading volume of 2,217,199 shares, compared to its average volume of 1,458,576. The business has a 50 day moving average of $26.76 and a 200-day moving average of $30.35. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Baillie Gifford & Co. acquired a new stake in shares of Heartflow during the third quarter worth $101,182,000. TD Asset Management Inc acquired a new position in Heartflow in the 3rd quarter valued at $2,692,000. New York State Common Retirement Fund purchased a new position in Heartflow during the 3rd quarter worth $4,015,000. Fred Alger Management LLC acquired a new stake in shares of Heartflow in the 3rd quarter worth $9,997,000. Finally, Artisan Partners Limited Partnership purchased a new stake in shares of Heartflow in the third quarter valued at about $16,817,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HTFL. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research note on Monday, December 29th. Wells Fargo & Company reduced their price objective on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday. JPMorgan Chase & Co. lowered their target price on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research report on Thursday. Finally, Canaccord Genuity Group lifted their target price on shares of Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.